Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/60532

TitlePTS micelles for the delivery of hydrophobic methotrexate
Author(s)Cerqueira, Patrícia
Noro, Jennifer Martins
Moura, Sofia
Guimarães, Diana
Silva, Carla
Cavaco-Paulo, Artur
Loureiro, Ana Isabel Sá
KeywordsPTS micelles
Methotrexate di-ethylated
Prodrug
Auxiliary solvent method
Sonication method
Cancer therapy
Issue date2019
PublisherElsevier
JournalInternational Journal of Pharmaceutics
CitationCerqueira, P.; Jennifer Noro; Moura, A.; Guimarães, Diana Isabel Pereira; Silva, Carla; Cavaco-Paulo, Artur; Loureiro, Ana, PTS micelles for the delivery of hydrophobic methotrexate. International Journal of Pharmaceutics, 566, 282-290, 2019
Abstract(s)Polyoxyethanyl--tocopheryl sebacate (PTS) is an amphiphilic compound with self-emulsifying properties known to form micelles. In this work, we report the production of PTS micelles for the encapsulation and delivery of a hydrophobic derivative of methotrexate, MTX di-ethylated (MTX-OEt). We optimized the micelles production by testing two different techniques: auxiliary solvent and sonication. Small and homogeneous micelles ( 40 nm) were obtained through the auxiliary solvent method performed at 30 °C and using 15 mg/mL of PTS. The produced micelles with the most promising physicochemical properties did not induce cytotoxicity when tested in normal human cells (BJ5ta cells), being considered for the encapsulation of MTX-OEt. This prodrug was achieved by Fisher esterification using ethanol, being isolated in good yield (= 68 %). MTX-OEt was efficiently encapsulated onto the produced micelles which preserved their physicochemical properties. The PTS micelles loaded with MTX-OEt, free MTX-OEt and free unmodified MTX revealed similar biological effect against cancer cells (Caco-2 cells). These results demonstrated that the biological activity of MTX is not altered after modification. The developed PTS micelles revealed a promising intracellular delivery performance with potentiality for cancer therapy.
TypeArticle
URIhttp://hdl.handle.net/1822/60532
DOI10.1016/j.ijpharm.2019.05.049
ISSN03785173
Publisher versionhttp://www.elsevier.com/locate/issn/03785173
Peer-Reviewedyes
AccessOpen access
Appears in Collections:CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series

Files in This Item:
File Description SizeFormat 
document_51726_1.pdf2,06 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID